≡

CLIA Kit for Bone Morphogenetic Protein 9 (BMP9)

GDF2; Growth Differentiation Factor 2

Specificity

This assay has high sensitivity and excellent specificity for detection of Bone Morphogenetic Protein 9 (BMP9).
No significant cross-reactivity or interference between Bone Morphogenetic Protein 9 (BMP9) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Bone Morphogenetic Protein 9 (BMP9) and the recovery rates were calculated by comparing the measured value to the expected amount of Bone Morphogenetic Protein 9 (BMP9) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 94-102 99
EDTA plasma(n=5) 80-94 88
heparin plasma(n=5) 79-103 91

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Bone Morphogenetic Protein 9 (BMP9) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Bone Morphogenetic Protein 9 (BMP9) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Bone Morphogenetic Protein 9 (BMP9) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 98-105% 78-103% 83-96% 80-89%
EDTA plasma(n=5) 80-89% 90-97% 90-97% 80-96%
heparin plasma(n=5) 83-105% 92-101% 87-95% 80-98%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Metabolism Bone morphogenic protein 9 is a novel thermogenic hepatokine secreted in response to cold exposure Pubmed:35063533
Heliyon Scaffolds of Bioactive Glass (Bioglass®) Combined with Recombinant Human Bone Morphogenetic Protein-9 (rhBMP-9) for Tooth Extraction Site Preservation Pubmed:35600439
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPB728Ra01 Recombinant Bone Morphogenetic Protein 9 (BMP9) Positive Control; Immunogen; SDS-PAGE; WB.
PAB728Ra01 Polyclonal Antibody to Bone Morphogenetic Protein 9 (BMP9) WB; IHC; ICC; IP.
MAB728Ra21 Monoclonal Antibody to Bone Morphogenetic Protein 9 (BMP9) WB; IHC; ICC; IP.
SEB728Ra ELISA Kit for Bone Morphogenetic Protein 9 (BMP9) Enzyme-linked immunosorbent assay for Antigen Detection.
SCB728Ra CLIA Kit for Bone Morphogenetic Protein 9 (BMP9) Chemiluminescent immunoassay for Antigen Detection.
LMB728Ra Multiplex Assay Kit for Bone Morphogenetic Protein 9 (BMP9) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.